<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35570247</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1619-1560</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical autonomic research : official journal of the Clinical Autonomic Research Society</Title><ISOAbbreviation>Clin Auton Res</ISOAbbreviation></Journal><ArticleTitle>A case series of cutaneous phosphorylated &#x3b1;-synuclein in Long-COVID POTS.</ArticleTitle><Pagination><StartPage>209</StartPage><EndPage>212</EndPage><MedlinePgn>209-212</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10286-022-00867-0</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miglis</LastName><ForeName>Mitchell G</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0001-8488-0313</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, 213 Quarry Road, Palo Alto, CA, 94304, USA. mmiglis@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seliger</LastName><ForeName>Jordan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, 213 Quarry Road, Palo Alto, CA, 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaik</LastName><ForeName>Ruba</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, 213 Quarry Road, Palo Alto, CA, 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbons</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Auton Res</MedlineTA><NlmUniqueID>9106549</NlmUniqueID><ISSNLinking>0959-9851</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="Y">Lewy Body Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>M. G. Miglis reports grant funding from Dysautonomia International, serves on the medical advisory board of Dysautonomia International (unpaid), and reports personal compensation for consulting work with MED-IQ, 2nd MD, and Infinite MD. C. Gibbons has served as a scientific advisor for CND Life Sciences, has stock options with CND Life Sciences, and has received personal compensation for his editorial activities (Associate Editor) with Autonomic Neuroscience Basic and Clinical. R. Shaik and J. Seliger report nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>15</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35570247</ArticleId><ArticleId IdType="pmc">PMC9108014</ArticleId><ArticleId IdType="doi">10.1007/s10286-022-00867-0</ArticleId><ArticleId IdType="pii">10.1007/s10286-022-00867-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Larsen NW, Stiles LE, Miglis MG. Preparing for the long-haul: autonomic complications of COVID-19. Auton Neurosci. 2021;235:102841. doi: 10.1016/j.autneu.2021.102841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autneu.2021.102841</ArticleId><ArticleId IdType="pmc">PMC8254396</ArticleId><ArticleId IdType="pubmed">34265539</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrams RMC, Simpson DM, Navis A, et al. Small fiber neuropathy associated with SARS-CoV-2 infection. Muscle Nerve. 2021 doi: 10.1002/MUS.27458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/MUS.27458</ArticleId><ArticleId IdType="pmc">PMC8661991</ArticleId><ArticleId IdType="pubmed">34766365</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Garcia J, Freeman R, Gibbons CH. Phosphorylated alpha-synuclein within cutaneous autonomic nerves of patients with Parkinson&#x2019;s disease: the implications of sample thickness on results. J Histochem Cytochem. 2020;68:669&#x2013;678. doi: 10.1369/0022155420960250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1369/0022155420960250</ArticleId><ArticleId IdType="pmc">PMC7534099</ArticleId><ArticleId IdType="pubmed">32921251</ArticleId></ArticleIdList></Reference><Reference><Citation>Provitera V, Gibbons CH, Wendelschafer-Crabb G, et al. A multi-center, multinational age- and gender-adjusted normative dataset for immunofluorescent intraepidermal nerve fiber density at the distal leg. Eur J Neurol. 2016;23:333&#x2013;338. doi: 10.1111/ene.12842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12842</ArticleId><ArticleId IdType="pubmed">26493160</ArticleId></ArticleIdList></Reference><Reference><Citation>Merello M, Bhatia KP, Obeso JA. SARS-CoV-2 and the risk of Parkinson&#x2019;s disease: facts and fantasy. Lancet Neurol. 2021;20:94. doi: 10.1016/S1474-4422(20)30442-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30442-7</ArticleId><ArticleId IdType="pmc">PMC7834123</ArticleId><ArticleId IdType="pubmed">33253627</ArticleId></ArticleIdList></Reference><Reference><Citation>Semerdzhiev SA, Fakhree MAA, Segers-Nolten I, et al. Interactions between SARS-CoV-2 N-protein and &#x3b1;-synuclein accelerate amyloid formation. ACS Chem Neurosci. 2022;13:143&#x2013;150. doi: 10.1021/ACSCHEMNEURO.1C00666/SUPPL_FILE/CN1C00666_SI_001.PDF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ACSCHEMNEURO.1C00666/SUPPL_FILE/CN1C00666_SI_001.PDF</ArticleId><ArticleId IdType="pmc">PMC8739828</ArticleId><ArticleId IdType="pubmed">34860005</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TD, Bellaire B, Gibbons C, Freeman R. Cutaneous alpha-synuclein deposition in postural tachycardia patients. Ann Clin Transl Neurol. 2021;8:908&#x2013;917. doi: 10.1002/ACN3.51347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ACN3.51347</ArticleId><ArticleId IdType="pmc">PMC8045934</ArticleId><ArticleId IdType="pubmed">33764697</ArticleId></ArticleIdList></Reference><Reference><Citation>Donadio V. Skin nerve &#x3b1;-synuclein deposits in Parkinson&#x2019;s disease and other synucleinopathies: a review. Clin Auton Res. 2019;29:577&#x2013;585. doi: 10.1007/S10286-018-0581-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S10286-018-0581-4</ArticleId><ArticleId IdType="pubmed">30506233</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoshnood RJ, Zali A, Tafreshinejad A, et al. Parkinson&#x2019;s disease and COVID-19: a systematic review and meta-analysis. Neurol Sci. 2022;43:775&#x2013;783. doi: 10.1007/s10072-021-05756-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05756-4</ArticleId><ArticleId IdType="pmc">PMC8596358</ArticleId><ArticleId IdType="pubmed">34787753</ArticleId></ArticleIdList></Reference><Reference><Citation>Doppler K, Jentschke H-M, Schulmeyer L, et al. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson&#x2019;s disease. Acta Neuropathol. 2017;133:535&#x2013;545. doi: 10.1007/s00401-017-1684-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1684-z</ArticleId><ArticleId IdType="pmc">PMC5348554</ArticleId><ArticleId IdType="pubmed">28180961</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23:210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Donadio V, Incensi A, Rizzo G, et al. Skin biopsy may help to distinguish multiple system atrophy-Parkinsonism from Parkinson&#x2019;s disease with orthostatic hypotension. Mov Disord. 2020;35:1649&#x2013;1657. doi: 10.1002/mds.28126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28126</ArticleId><ArticleId IdType="pubmed">32557839</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>